Fosmidomycin (sodium salt)
(Synonyms: 膦胺霉素,Antibiotic FR31564,FR31564) 目录号 : GC12939Fosmidomycin (sodium salt)是1-脱氧-d-木酮糖5-磷酸还原异构酶（DXP）的特异性抑制剂。
Cas No.:66508-37-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
Cell lines | E. coli cells |
Preparation Method | A 3h-old wild-type E. coli strain suspension was spread out on LB-agar plates containing Fosmidomycin (from 0 to 100µM). After 24h, 48h and 72h, the number of colonies was counted. Exceeding the value of 200 colonies indicates the formation of a lawn of bacteria. |
Reaction Conditions | 0-100µM; 24h, 48h and 72h |
Applications | E. coli developed resistance to Fosmidomycin within 24h, with resistance developing more rapidly at lower concentrations. |
| Animal experiment [2]: | |
Animal models | Plasmodium vinckei mouse model |
Preparation Method | Mice were inoculated by intraperitoneal injection with approximately 5×107 infected erythrocytes from a donor mouse. Fosmidomycin was dissolved in phosphate-buffered saline and administered orally (75mg/kg of body weight). Clindamycin hydrochloride was dissolved in distilled water and administered by intraperitoneal injection (5mg/kg). Four mice were used for each treatment group, and three mice were used for the control group. Drugs were given on days 1 and 2 postinfection, and parasitemia was monitored on days 3 to 5. Parasitemia was monitored by Giemsa staining of blood smears. Mice were sacrificed when parasitemia exceeded 40%. |
Dosage form | 75mg/kg, on days 1 and 2; p.o. |
Applications | On day 3, the parasitemia of mice treated with 75mg/kg of Fosmidomycin or 5mg/kg of clindamycin was 7.8 or 20%, respectively, in comparison to 42% in untreated control mice. When the mice were treated with a combination of 75 mg/kg of Fosmidomycinand 5.0mg/kg of clindamycin, the parasitemia was approximately 0.1% on day 3, increasing to 0.2% on day 5. |
References: [1]Hemmerlin A, Tritsch D, Hammann P, et al. Profiling of defense responses in Escherichia coli treated with fosmidomycin[J]. Biochimie, 2014, 99: 54-62. [2]Wiesner J, Henschker D, Hutchinson D B, et al. In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin[J]. Antimicrobial Agents and Chemotherapy, 2002, 46(9): 2889-2894. | |
Fosmidomycin (sodium salt) is a specific inhibitor of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXP)[1]. Fosmidomycin is a phosphate antibiotic isolated from Streptomyces that is active against both Gram-negative and Gram-positive bacteria[2]. Fosmidomycin is an effective and safe antimalarial drug[3]. Fosmidomycin inhibits the second reaction in the non-mevalonate pathway of isoprene biosynthesis, which is an important pathway for many obligate intracellular pathogens, including mycobacteria and apicomplexan parasites[4].
In vitro, Escherichia coli cells treated with Fosmidomycin (0-100µM) for 24-72h developed resistance to Fosmidomycin within 24h, and resistance developed more rapidly at lower concentrations[5]. Fosmidomycin (0.25-2mM) treatment of HeLa cells infected with Chlamydia does not inhibit the ability of Chlamydia to infect HeLa cells, but it does prevent the development and production of inclusion bodies in infectious offspring[6].
In vivo, Fosmidomycin (75mg/kg) was administered orally to treat mice infected with Plasmodium vinckei for 2 days and effectively treated the parasitemia of mice. The effect was better when combined with clindamycin[7].
References:
[1] Kuzuyama T, Shimizu T, Takahashi S, et al. Fosmidomycin, a specific inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway for terpenoid biosynthesis[J]. Tetrahedron letters, 1998, 39(43): 7913-7916.
[2] Parkinson E I, Erb A, Eliot A C, et al. Fosmidomycin biosynthesis diverges from related phosphonate natural products[J]. Nature chemical biology, 2019, 15(11): 1049-1056.
[3] Missinou M A, Borrmann S, Schindler A, et al. Fosmidomycin for malaria[J]. The Lancet, 2002, 360(9349): 1941-1942.
[4] Sparr C, Purkayastha N, Kolesinska B, et al. Improved efficacy of fosmidomycin against Plasmodium and Mycobacterium species by combination with the cell-penetrating peptide octaarginine[J]. Antimicrobial agents and chemotherapy, 2013, 57(10): 4689-4698.
[5] Hemmerlin A, Tritsch D, Hammann P, et al. Profiling of defense responses in Escherichia coli treated with fosmidomycin[J]. Biochimie, 2014, 99: 54-62.
[6] Slade J A, Brockett M, Singh R, et al. Fosmidomycin, an inhibitor of isoprenoid synthesis, induces persistence in Chlamydia by inhibiting peptidoglycan assembly[J]. PLoS pathogens, 2019, 15(10): e1008078.
[7] Wiesner J, Henschker D, Hutchinson D B, et al. In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin[J]. Antimicrobial Agents and Chemotherapy, 2002, 46(9): 2889-2894.
Fosmidomycin (sodium salt)是1-脱氧-d-木酮糖5-磷酸还原异构酶（DXP）的特异性抑制剂[1]。Fosmidomycin是一种从链霉菌属细菌中分离出来的磷酸抗生素，对革兰氏阴性菌和革兰氏阳性菌均有活性[2]。Fosmidomycin是一种有效且安全的抗疟药[3]。Fosmidomycin能够抑制异戊二烯生物合成的非甲羟戊酸途径中的第二个反应，该途径是许多专性细胞内病原体（包括分枝杆菌和顶复门寄生虫）的重要途径[4]。
在体外，Fosmidomycin（0-100µM）处理大肠杆菌细胞24-72h，在24小时内细胞就对磷胺霉素产生了抗性，且浓度越低抗性出现得越快[5]。Fosmidomycin（0.25-2mM）处理感染了衣原体的HeLa细胞，不会抑制衣原体感染HeLa细胞的能力，但会阻止感染性后代的包涵体发育和产生[6]。
在体内，Fosmidomycin（75mg/kg）通过口服给药治疗文氏疟原虫（Plasmodium vinckei）感染小鼠2天，有效治疗了小鼠的寄生虫血症，与克林霉素联合治疗效果更佳[7]。
| Cas No. | 66508-37-0 | SDF | |
| 别名 | 膦胺霉素,Antibiotic FR31564,FR31564 | ||
| 化学名 | P-[3-(formylhydroxyamino)propyl]-phosphonic acid, monosodium salt | ||
| Canonical SMILES | ON(C([H])=O)CCCP([O-])(O)=O.[Na+] | ||
| 分子式 | C4H9NO5P • Na | 分子量 | 205.1 |
| 溶解度 | ≤5mg/ml in PBS, pH 7.2 | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.8757 mL | 24.3784 mL | 48.7567 mL |
| 5 mM | 0.9751 mL | 4.8757 mL | 9.7513 mL |
| 10 mM | 0.4876 mL | 2.4378 mL | 4.8757 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。